Insulin Market By Type (Rapid-acting insulin, Short-acting insulin, Intermediate-acting insulin, Long-acting insulin, Premixed insulin, Insulin biosimilars), By Delivery Mode (Injectable insulin, Insulin pumps, Inhalable insulin, Insulin patches), By Application (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, Diabetes-related Complications), By End-User (Hospitals, Home care, Clinics, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Insulin market accounted for USD 22.65 Billion in 2024 and is expected to reach USD 37.54 Billion by 2035, growing at a CAGR of around 4.7% between 2025 and 2035. The Insulin Market encompasses the global industry for the production and distribution of insulin and diabetes-related products. There are three major options for the medical management of diabetes; insulin is the most common treatment for diabetics who lack or have a suboptimal intrinsic ability to synthesize and metabolize insulin.

The types of insulin available in the market include initial formulations of rapid-acting, long-acting, and intermediate-acting products; and advanced technology including insulin pens, pumps, and the more recently introduced CGM system in a single product. In the Insulin Market. The market also comprises insulin products in pens, vials, and pumps offered by market players including Novo Nordisk, Sanofi, and Eli Lily. It also has a new segment with biosimilar insulin to enhance the availability and cost of the product.

Report Scope:

Market Dynamics

Rising prevalence of diabetes globally, driven by lifestyle changes and aging populations

The world Insulin Market remains intact & growing due to the growing number of diabetic patients worldwide infectious by modified life standards, including increasing lethargy, unhealthy diets, and an aging population. The International Diabetes Federation (IDF) predicts an enormous growth in the number of people with diabetes in the future, which will require efficient insulin products. Obesity and urbanization add to this by increasing the demand for new and better insulin delivery systems.

Heightened awareness of this disease, along with rising healthcare expenses and state programs aimed at diabetes prevention, is contributing to market growth. This expansion is further supported by advancements in biosimilar insulin and smart insulin delivery systems, which offer improved convenience and effectiveness for patients.

Advancements in insulin delivery technologies enhancing patient compliance and therapeutic efficacy

Innovations in the Insulin Market are introducing new devices that enhance diabetes treatment, improving patient compliance and the effectiveness of therapy. Key advancements include smart insulin pens, cutting-edge integrated continuous glucose monitoring (CGM) systems combined with insulin pumps, and next-generation long-acting insulin. These innovations allow for accurate dosing, reducing the fear of hypoglycemia and improving glycemic control. Additionally, wearable devices and artificial pancreas systems provide automated insulin delivery, making it easier for patients to adhere to their prescribed treatment regimens.

Progress in developing needle-free delivery systems and oral insulin formulations is a promising solution for diabetes management. Recent advancements in the Insulin Market are driven by AI analysis, which enables real-time personalization of therapy. Ongoing studies continue to emerge, and there is a growing demand for more user-friendly and affordable alternatives to enhance the quality of life for diabetes patients around the world.

Limited awareness and diagnosis of diabetes in developing regions hindering treatment adoption

Diabetes is often not diagnosed early in developing countries, which significantly hinders the growth of the Insulin Market since patients are unable to transition to the appropriate treatment they require. Most people are still out of reach of screening programs or lack access to healthcare centers, hence they retain their diabetic status unknown. Cultural taboos, a lack of knowledge about the disease, and misconceptions about insulin, which are drawn from movies and fiction, only worsen the situation, while the patients receive inadequate or no treatment for diabetes at all.

This lack of awareness does more than affect patient outcomes but also limits the extent to which insulin products can penetrate such markets. However, expanded diabetes cases are still a challenge to the Insulin Market regarding reaching diverse underserved populations. To mitigate these challenges, education and early intervention coupled with lower-cost insulin products are the major ways to increase adherence and develop a greater marketplace.

Expansion of Insulin Markets in emerging economies with rising healthcare infrastructure

The Insulin Market is growing due to enormous advancements that have been made in the healthcare infrastructure of emerging economies with corresponding increases in expenditures on medical facilities care. Since people within these regions are attaining better health care services as influenced by rising urbanization and economic development, there is proper time for diagnosis and treatment of diabetes complications. The government plans to implement coagulation therapies and insulin therapy subsidizing programs to extend people’s awareness and promote market growth.

The rising incidence rate of diabetes within the emerging markets affecting a globalizing world through changes in diet and the aging demographics contributes to the consistent demand for insulin ingredients. To this end, pharmaceutical firms are innovating biosimilar insulin that is cheaper for the said markets as well as delivery devices. This expansion not only improved diabetes care, but also greatly expanded the global Insulin Market.

Integration of digital health technologies with insulin delivery for better diabetes management

The presence of digital health technologies in insulin delivery systems is slowly changing the Insulin Market and enhancing the outcomes of the management of diabetes. Automated insulin delivery, digital CGM, and technology-based support applications have become highly integrated, where one gets instant information regarding the users’ blood glucose level and insulin administration. These technologies make it possible for patients and caregivers to make decisions that help avoid complications and get diabetes to the required level of glycemic.

These systems include the hybrid closed-loop insulin pump and the artificial pancreas system that incorporates an insulin infusion system monitoring with AI analysis for an individual approach to therapy. This integration also maximizes patient compliance and improves preventive diabetes care since it also explains the effect of certain lifestyles on blood sugar levels. With digital health advancing over time, the complementary relationship between digital health and insulin delivery is keeping the Insulin Market vibrant.

Industry Experts Opinion

“The vast majority of diabetics that are insulin-dependent are injecting themselves with insulin, and doing their very best, but they do not have healthy blood sugar levels, if you look at their blood sugar levels, even for people that are very dedicated to being careful, they just can’t match what a living pancreas can do.”

• Daniel Anderson, Professor, MIT’s Department of Chemical Engineering.

“Understanding glucose levels is key to unlocking our metabolic health, and Stelo will help users see first-hand how their health is affected by factors such as diet, exercise, sleep, and stress.”

• Jake Leach, COO, Dexcom EVP.

Segment Analysis

Based on Type, the Insulin Market is classified into Rapid-acting insulin, Short-acting insulin, Intermediate-acting insulin, Long-acting insulin, Premixed insulin, and Insulin biosimilar. The three commonly used types of insulin include rapid-acting and short-acting insulin which is useful in managing postprandial hyperglycemia and intermediate-acting and long-acting insulin which is used in maintaining people’s blood glucose levels low for the longest possible time. Premeal insulin consists of rapid and intermediate-acting insulins for those patients who require both basal and meal-related insulin.

The utilization of insulin biosimilars has been on the rise because they offer an affordable option for expensive branded insulin. The biosimilar segment is expected to grow at a fast rate due to the rising need for cheaper insulin in the global market, particularly in developing nations. Ongoing innovation in insulin formulations including Ultra-long-acting insulins is also supporting this segment’s growth.

Based on Delivery mode, the Insulin market is classified into injectable insulin, insulin pump, inhalable insulin, and insulin patches. Vial and soluble insulin remain the most used injection type because it is easy to use and effective. There are several types of insulin injections, including pre-filled pens. Currently, more patients use insulin pumps because it is an effective technology that provides constant insulin infusion and eliminates multiple injections. Inhalable insulin has begun to be the non-injection insulin since it is gaining much demand from those who prefer getting less invasive therapies.

And finally, new insulin patches are being engineered to provide the hormone with a non-invasive patch method to fight against the disease of diabetes. The key growth driver for the delivery modes segment is the fact that patients desire more convenient, less invasive, and technologically superior delivery systems, particularly in high-prevalence diabetes care countries/Europe.

Regional Analysis

North America is the largest region of the Insulin Market owing to a large number of diabetic patients and the well-developed healthcare sector of the region. America heads the list of innovating nations, and the companies Novo Nordisk, Sanofi, and Eli Lilly are continuously launching new-generation insulin including the ultra-rapid-acting insulin and smart insulin pens.

The region has also experienced an increase in the uptake of biosimilar insulin, with assistance from the FDA as far as regulations are concerned. Besides, technological advancement in the management of diabetes is being facilitated by new smart technologies such as continuous glucose monitoring systems combined with an insulin delivery system. Canada makes a perfect partner to the US market by having a strong government support for cheap insulin that helps in establishing biosimilar insulins. In conclusion, North America continues to dominate the Insulin Market revenue on the global market.

Asian-Pacific accounts for the fastest-growing region in the Insulin Market due to budding diabetes prevalence and health care and urbanization. India and China are growing economies that require more affordable insulin production. Developments in this region involve unique strategies that include collaboration between global and local players, such as Biocon and Mylan working together to produce biosimilar insulin.

The governments of this region are launching campaigns about diabetes awareness and enhancing the healthcare policies that are driving the Insulin Market. Factors that readily propose adoption include the development of oral insulin and cheap substitute analog insulins. The rise in insulin pen and insulin pump use negotiated the shift towards more sophisticated systems of insulin delivery in the region. The growth in the latest years of Asia-Pacific’s healthcare industry guarantees its strategic importance for the global Insulin Market.

Competitive Landscape

The Insulin Market is very concentrated, with various large-scale global pharmaceutical companies including Novo Nordisk, Sanofi, Eli Lilly, and others for the leading market share of insulin. These businesses concentrate on innovations offering highly specialized forms of insulin such as ultra-rapid-acting insulin and long-acting basal integrated insulin analogs that will improve patient compliance and outcomes. Currently, biosimilar insulins from players like Mylan (Viatris) and Biocon are picking up because of the need to have affordable solutions.

The latest products that have been embarked on include the Novo Nordisk ‘Icodec’ which is a basal insulin given once a week and Sanofi ‘Toujeo’ which has better glycemic improvement than another insulin. They are also purchasing remote monitoring systems, like Eli Lilly’s Connected Pens, to combine insulin delivery with diabetes management applications. In Gan & Lee, some emerging players are expanding through collaboration to enter other countries’ markets. The rivalry map is strengthened by the regional players, cooperation, and the growing emphasis on oral and non-invasive insulin delivery systems, which shows that the market has great growth opportunities.

Insulin Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In December 2024, Sanofi announced its largest-ever investment in China, committing €1 billion ($1.04 billion) to establish a new insulin production facility in the Beijing Economic and Technological Development Zone. This strategic manufacturing expansion represents a calculated response to China’s growing diabetes crisis, with recent data indicating 140 million adults living with diabetes as of 2021.
• In July 2024, Tandem Diabetes Care and Dexcom announced the updated slim X2 insulin pump software. It is compatible with Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems and is authorized for sale by Health Canada.

Report Coverage:

By Type

• Rapid-acting insulin
• Short-acting insulin
• Intermediate-acting insulin
• Long-acting insulin
• Premixed insulin
• Insulin biosimilars

By Delivery Mode

• Injectable insulin
• Insulin pumps
• Inhalable insulin
• Insulin patches

 By Application

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes
• Diabetes-related Complications

By End-User

• Hospitals
• Home care
• Clinics
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Novo Nordisk
• Sanofi
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Eli Lilly and Co.
• Bayer AG
• AbbVie
• Mylan
• Wockhardt Ltd.
• Roche
• Teva Pharmaceutical Industries
• Gan & Lee Pharmaceuticals
• Hypertension Pharmaceuticals
• Julphar
• Cipla
• Shanghai Fosun Pharmaceutical
• Oramed Pharmaceuticals
• Lexicon Pharmaceuticals

Frequently Asked Questions (FAQs)